Skip Navigation Links
A Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata.
Overall Recruitment Status: Active, enrollment completed
 
Official Title
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata.
 
Region Sponsors
California - Northern
Concert Pharmaceuticals
 
Acronym KP IRB No.
CTP-543 1405545
 
Study Type Phase
Clinical Trial Phase II
 
Study Population Description
Alopecia Areata.
 
Purpose
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
 
Detailed Description
This is a Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata.
 
Gender Age Limit
Male & Female 18 - 65 years
 
Inclusion Criteria
  • Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial
 
Exclusion Criteria
  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
  • Donation of blood at any point throughout the study and for 30 days after last dose of study medication

 
Keywords and/or Specific Medical Conditions
  • Alopecia Areata
  • Skin Diseases
  • Hair Diseases
  • Alopecia
  • Hypotrichosis
  • Dermatology
  • Pathological Conditions, Anatomical
  • Pathology
 
KP Clinical Facility
 
Clinical Area
  • Dermatology
  • Pathology


Principal Investigator:
Paradi Mirmirani, MD
Contact Information:
- Daisy Mendoza-Zepeda
-Central Valley-Manteca


smilelady1
Do you want to receive
Email Alerts?

Sign Up Here!





Regional Research Sites: